申请人:Cheng Leifeng
公开号:US20080287517A1
公开(公告)日:2008-11-20
The present invention relates to compounds of formula I
wherein R
1
represents a group R
5
O— in which R
5
represents a C
3-7
alkyl group substituted by one or more fluoro or R
5
represents a C
3-7
alkylsulphonyl group which is optionally substituted by one or more fluoro; R
2
represents a C
1-4
alkyl group, hydroxy, fluoro, chloro or cyano wherein each R
2
is independently selected when n is >1; R
3
represents a) cyclohexyl optionally substituted by one or more of the following: hydroxy, fluoro, amino, mono or diC
1-3
alkylamino, carboxy or a C
1-4
alkoxycarbonyl group b) piperidino substituted by one or more hydroxy c) unsubstituted piperidino but only when one of the following applies: R
4
represents cyano or R
1
represents 3-fluoropropylsulphonyloxy or R
1
represents 3,3,3-trifluoropropoxy or R
1
represents 3-fluoropropoxy or R
2
is methyl d) phenyl substituted by one or more of the following: hydroxy, halo or a C
1-4
alkyl group e) pyridyl substituted by a C
1-4
alkyl group or f) a C
4-9
alkyl group; R
4
represents cyano or methyl; and n is 1, 2 or 3 and pharmaceutically acceptable salts thereof and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.
本发明涉及一种式I的化合物,其中R1表示R5O-基团,其中R5表示一个C3-7烷基基团,该基团被一个或多个氟代或R5表示一个C3-7烷基磺酰基团,该基团可被一个或多个氟代取代;R2表示C1-4烷基基团,羟基,氟,氯或氰,其中当n>1时,每个R2是独立选择的;R3表示a)环己基,可选地被以下一种或多种取代:羟基,氟,氨基,单或双C1-3烷基氨基,羧基或C1-4烷氧羰基基团b)哌啶取代的羟基或多个羟基c)未取代的哌啶,但仅当以下之一适用时:R4表示氰基或R1表示3-氟丙基磺酰氧基或R1表示3,3,3-三氟丙氧基或R1表示3-氟丙氧基或R2为甲基d)苯基,可选地被以下一种或多种取代:羟基,卤素或C1-4烷基基团e)吡啶基,取代为C1-4烷基基团或f)C4-9烷基基团;R4表示氰基或甲基;n为1、2或3,以及其药学上可接受的盐和制备这种化合物的过程,它们在肥胖症、精神和神经疾病的治疗中的用途,以及它们的治疗用途的方法和包含它们的制药组合物。